ADRB3 and myocardial infarction: A similar antifibrotic effect was also observed following myocardial infarction upon treatment of mice with β3-AR agonists [53] along with a reduced scar area and apoptosis [53,59] yet was not replicated in mice submitted to TAC and treated with the β3-AR agonist BRL-37344; this was most likely explained by the low basal level of expression of endogenous cardiac β3-AR in mice and the short timing of investigation following TAC (i.e., one and three weeks post-TAC vs. 9 weeks in all other studies) [52].